Search - tctmd.com

Displaying 1 - 20 of 739

Sort: Relevancy | Date

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Thrombolysis May Be OK for DOAC-Treated Patients With Ischemic Stroke

Todd Neale

January 07, 2026

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Daily News

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Michael O'Riordan

November 24, 2025

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

L.A. McKeown

October 09, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

Advertisement

January 2026 Dispatch for the CV Team

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Thrombolysis May Be OK for DOAC-Treated Patients With Ischemic Stroke

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

TCTMD’s Top 10 Most Popular Stories for November 2025

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

October 2025 Dispatch for the CV Team

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Risk Factors Present in Nearly All Patients Who Develop CVD

September 2025 Dispatch for the CV Team

CVD Still the Leading Cause of Death and Disease Globally

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content